Center for Science in the Public Interest (url)
I could spend hours on this website!
I could spend hours on this website!
| By: cben | ||
|
"To “Raise A Voice” for our unified dissatisfaction with recent FDA Provenge ruling, and gain news coverage as the largest D.C. prostate cancer rally ever held (350 or more). We are raising a voice for prostate cancer once again, and the unmet need for more treatment options for advanced prostate cancer patients. We are building on what we accomplished together at the March 29th FDA Advisory Committee review meeting for Provenge (see below)." |
Latest treatments shown at conference
By Judy Peres
Tribune staff reporter
Published June 3, 2007
Patients with advanced head and neck cancer live significantly longer when a synthetic antibody is added to standard chemotherapy, a study shows.
The study, presented Saturday at the annual meeting of the American Society of Clinical Oncology at Chicago’s McCormick Place, was one of several showcasing new drugs that home in on cancer cells, largely sparing patients the side effects of conventional drugs.
"With new, targeted agents such as cetuximab [also known by the trade name Erbitux], we are on the brink of changing the way we treat patients with head and neck cancers," said Dr. Jan Baptiste Vermorken of the University of Antwerp, Belgium.continued ….
The more than 31,000 cancer experts at the meeting were greeted Saturday by about a dozen prostate-cancer activists protesting the Food and Drug Administration’s failure to approve a new drug. The agency announced last month that it wanted additional data before clearing Provenge, a therapeutic vaccine, although an advisory committee in March found the drug safe and effective.
Protesters carried signs stating, "My Prostate, My Choice" and "Safer Humane Treatments Today" among other slogans.
jperes@tribune.com